206-9C09 Fab in complex with HIV-1 GT1.1 v4.1 SOSIP Env trimer and RM20A3 Fab
N-acetyl-beta-D-glucosamine; 2-acetamido-2-deoxy-beta-D-glucose; 2-acetamido-2-deoxy-D-glucose; 2-acetamido-2-deoxy-glucose; N-ACETYL-D-GLUCOSAMINE
Precise targeting of HIV broadly neutralizing antibody precursors in humans.
EVQLVETGGGLVQPGGSLKLSCRASGYTFSSFAMSWVRQAPGKGLEWVSLINDRGGLTFYVDSVKGRFTISRDNSKNTLS LQMHSLRDGDTAVYYCATGGMSSALQSSKYYFDFWGQGALVTVSS
ALTQPPSVSGSPGQSVTISCTGTSSDIGSYNYVSWYQQHPGKAPKLMIYDVTQRPSGVSDRFSGSKSGNTASLTISGLQA DDEADYYCSAYAGRQTFYIFGGGTRLTVLGQPKASPTVTLFPPSSEEL
MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARAENLWVTVYYGVPVWKDAETTLFCASDAKAYETKKHNVWATHACV PTDPNPQEIHLENVTEEFNMWKNNMVEQMHTDIISLWDQSLKPCVKLTPLCVTLQCTNVTNNITDDMRGELKNCSFNMTT ELRDKRQKVHALFYKLDIVPINENQNTSYRLINCNTAAITQACPKVSFEPIPIHYCAPAGFAILKCKDKKFNGTGPCPSV STVQCTHGIKPVVSTQLLLNGSLAEEEVMIRSKDIRNNAKNILVQFNTPVQINCTRPNNNTRKSIRIGPGQWFYATGDII GDIRQAHCNVSKATWNETLGKVVKQLRKHFGNNTIIRFANSSGGDLEVTTHSFNCGGEFFYCDTSGLFNSTWISNTSVQG SNSTGSNDSITLPCRIKQIINMWQRIGQAMYAPPIQGVIRCVSNITGLILTRDGGSTDSTTETFRPSGGDMRDNWRSELY KYKVVKIEPLGVAPTRCKRRVVGRRRRRR
AVGIGAVFLGFLGAAGSTMGAASMTLTVQARNLLSGIVQQQSNLLRAPEAQQHLLKLTVWGIKQLQARVLAVERYLRDQQ LLGIWGCSGKLICCTNVPWNSSWSNRNLSEIWDNMTWLQWDKEISNYTQIIYGLLEESQNQQEKNEQDLLALD
QVQVVQSGAEVKKPGASVKVSCKASGYTFTDHYIHWVRQAPGQGLEWMGWINPYRGGTNYAQKFQGRVTMTRDTSINTAY MELSRLRFDDTAVYYCARPKDCSGGSCYDFDYWGQGTLVTVSS
NIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTHFTFTISRLQP EDIATYYCQVYETFGQGTKVEIK
REAL-SPACE (WEIGHTED MAP SUM AT ATOM CENTERS)
HIV-1, SOSIP, germline targeting, VRC01, clinical trial, human, precursor antibody, VIRAL PROTEIN
AVGIGAVFLGFLGAAGSTMGAASMTLTVQARNLLSGIVQQQSNLLRAIEAQQHLLKLTVWGIKQLQARVLAVERYLRDQQ LLGIWGCSGKLICTTNVPWNSSWSNRNLSEIWDNMTWLQWDKEISNYTQIIYGLLEESQNQQEKNEQDLLALD